| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| ln Vitro |
Adenosine 5'-diphosphate is made up of the nucleobase adenine, a pentose sugar called ribose, and a pyrophosphate group. The end result of ATP dephosphorylation by ATPase is adenosine 5'-diphosphate. Reconverting ADP to ATP is the function of ATP synthase. Within cells, ATP is a crucial component for energy transfer. Numerous cellular functions, such as motility, cell division, respiration, and metabolic activities, depend on adenosine 5'-diphosphate.
|
|---|---|
| References |
[1]. Arts IC, et al. Adenosine 5'-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans. J Int Soc Sports Nutr. 2012 Apr 17;9(1):16.
[2]. Noel J. Cusack, et al. Effects of phosphate-modified analogs of adenosine 5′-diphosphate and adenosine 5′‐triphosphate at P2T-purinoceptors mediating human platelet activation by ADP. April 1996. [3]. Adenosine-5'-diphosphate |
| Additional Infomation |
ADP is a purine ribonucleoside 5'-diphosphate having adenine as the nucleobase. It has a role as a human metabolite and a fundamental metabolite. It is an adenosine 5'-phosphate and a purine ribonucleoside 5'-diphosphate. It is a conjugate acid of an ADP(3-) and an ADP(2-).
Adenosine diphosphate is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Adenosine-5'-diphosphate has been reported in Helianthus tuberosus, Arabidopsis thaliana, and other organisms with data available. ADP is a metabolite found in or produced by Saccharomyces cerevisiae. Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. |
| Molecular Formula |
C10H15N5O10P2
|
|---|---|
| Molecular Weight |
427.2011
|
| Exact Mass |
427.029
|
| CAS # |
58-64-0
|
| PubChem CID |
6022
|
| Appearance |
White to off-white solid powder
|
| Density |
2.5±0.1 g/cm3
|
| Boiling Point |
877.7±75.0 °C at 760 mmHg
|
| Flash Point |
484.6±37.1 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.905
|
| LogP |
-2.91
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
P(=O)(O[H])(OP(=O)(O[H])O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3=C(N([H])[H])N=C([H])N=C23)O1)O[H])O[H]
|
| InChi Key |
XTWYTFMLZFPYCI-KQYNXXCUSA-N
|
| InChi Code |
InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
|
| Chemical Name |
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~117.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (234.08 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3408 mL | 11.7041 mL | 23.4082 mL | |
| 5 mM | 0.4682 mL | 2.3408 mL | 4.6816 mL | |
| 10 mM | 0.2341 mL | 1.1704 mL | 2.3408 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01557335 | Completed | Drug: Plavix® and PA32540 | Platelet Aggregation | POZEN | November 2010 | Phase 1 |
| NCT02699008 | Completed | Drug: Clopidogrel Drug: Ticagrelor |
Acute Coronary Syndrome | Wuhan Asia Heart Hospital | January 2014 | Not Applicable |
| NCT01088503 | Completed Has Results | Drug: ADP receptor inhibitors | Acute Coronary Syndrome | Eli Lilly and Company | March 2010 | |
| NCT01129375 | Completed | Drug: clopidogrel Drug: placebo |
Healthy | Sanofi | February 2009 | Phase 1 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
